Stilla Technologies completes €16 Million ($18 Million) Series A Illumina Ventures led the financing round
- Objective: financing to commercialize its novel digital PCR system and develop clinical applications.
Paris, November 20th, 2018. Stilla Technologies, the European provider of pioneering digital PCR solutions for high precision genetic analysis, announced today the successful completion of a Series A financing round of 16 million euros ($18 Million) led by Illumina Ventures, with participation from Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds & Idinvest Partners. As part of the financing, Nick Naclerio (Illumina Ventures), Philippe Peltier (Kurma Partners) and Philippe Chambon (LBO France) have joined the board of directors, replacing the seed investors.
Since 2016, Stilla Technologies has been providing research organizations specialized in molecular biology and genetic analysis with its naica® System, a ground-breaking digital PCR solution that enables scientists to detect and quantify DNA mutations with unrivalled precision.
“With our naica® System, researchers worldwide are building a new generation of high-precision genetic tests, in various fields of applications such as liquid biopsy tests for cancer diagnostics, pre-natal testing or GMO detection” commented Rémi Dangla, CEO and co-founder of Stilla Technologies.”The additional financing will enable Stilla to accelerate the sales of the naica® System, , launch our 2nd generation solution, and begin clinically validating panels to be run on the system with an initial focus in the field of oncology.”
“We are very excited to be working with Stilla and such a deep syndicate of European investors added Nick Naclerio, Founding Partner of Illumina Ventures. “The Stilla team has done an amazing job developing and launching the naica® system in Europe and Asia with a very limited amount of seed financing. With these additional resources, we believe that Stilla Technologies can become a global leader in digital PCR and the lowest cost platform for liquid biopsies.”
Stilla Technologies will be presenting its latest products and developments in the field of digital PCR at the upcoming annual 4BIO Summit – Europe in Rotterdam, Netherlands on the 27th and 28th of November 2018.